Skip to main content

Table 4 Logistic regression for risk factors for incontinence and impotence

From: Free testosterone value before radical prostatectomy is related to oncologic outcomes and post-operative erectile function

Variables

Pre-operative ED

Post-operative ED

Post-operative incontinence

OR

95%CI

p value

OR

95%CI

p value

OR

95%CI

p value

TT (normal vs low)

0.525

0.322–0.856

0.010*

1.580

0.491-5.076

0.443

1.566

0.540–4.540

0.409

FT (normal vs low)

0.824

0.433–1.570

0.557

0.332

0.180–0.612

< 0.001*

0.885

0.368–2.128

0.784

Age(continuous)

1.107

1.074–1.141

< 0.001*

1.118

1.076-1.161

< 0.001*

1.039

1.003-1.076

0.034*

BMI (continuous)

0.968

0.918–1.021

0.232

0.973

0.911–1.039

0.493

1.033

0.961–1.111

0.377

Diabetes (presence vs absence)

0.846

0.519–1.378

0.502

1.073

0.573–2.008

0.826

1.095

0.543–2.210

0.800

Hypertension (presence vs absence)

0.784

0.457–1.347

0.379

0.760

0.404–1.428

0.393

1.115

0.549–2.265

0.764

Coronary heart disease (presence vs absence)

1.443

0.803–2.594

0.221

0.732

0.336–1.596

0.433

0.813

0.346–1.909

0.634

Smoke (presence vs absence)

2.450

1.477–4.064

0.001*

0.720

0.352-1.470

0.366

0.794

0.370–1.705

0.555

Alcohol (presence vs absence)

1.197

0.768–1.867

0.427

1.102

0.617–1.969

0.742

0.800

0.421–1.522

0.496

PSA (≥10 ng/ml vs < 10 ng/ml)

1.511

0.997–2.289

0.052

0.806

0.495–1.311

0.384

0.842

0.486–1.459

0.539

Proportion of free-PSA (≥ 0.16 vs < 0.16)

1.333

0.878–2.023

0.177

0.899

0.530–1.527

0.694

0.931

0.523–1.656

0.807

Clinical Tumor stage (T2a vs T3)

0.479

0.244–0.939

0.032*

      

Clinical (T2b vs T3)

0.949

0.558–1.613

0.847

      

Clinical (T2c vs T3)

0.655

0.400–1.072

0.092

      

Biopsy Gleason Score (6 vs 8 or higher)

0.829

0.470–1.462

0.518

      

Biopsy Gleason Score (7 vs 8 or higher)

0.823

0.523–1.294

0.398

      

Surgical approach (open vs laparoscopic)

   

0.616

0.385–0.986

0.044*

0.972

0.580-1.628

0.913

NVB preserve(presence vs absence)

   

1.479

0.890–2.456

0.131

1.069

0.621–1.840

0.809

Pathological Tumor stage (T2a vs T3)

   

0.806

0.350–1.859

0.614

1.614

0.634–4.112

0.316

Pathological Tumor stage (T2b vs T3)

   

1.096

0.553–2.171

0.794

1.700

0.793–3.645

0.173

Pathological Tumor stage (T2c vs T3)

   

1.177

0.638–2.196

0.602

1.274

0.617–2.629

0.513

Final Gleason Score (6 vs 8 or higher)

   

0.555

0.280–1.100

0.092

1.134

0.513–2.510

0.756

Final Gleason Score (7 vs 8 or higher)

   

0.466

0.263–0.826

0.009*

0.976

0.514–1.852

0.940

Lymph node status (N- vs N+)

   

2.242

0.638–7.877

0.208

3.202

0.393–26.079

0.277

Lymph node status (Nx vs N+)

   

3.344

0.962–11.623

0.058

2.864

0.349–23.489

0.327

PSM (presence vs absence)

   

0.722

0.304–1.716

0.460

1.005

0.364–2.773

0.993

  1. OR odds Ratio; CI confidence interval; ED erectile dysfuncion;TT total testosterone; FT free testosterone; PSA prostate-specific antigen; BMI body mass index; PSM positive surgical margin; NVB neurovascular bundle
  2. p value of less than 0.05 are in boldface
  3. *Statistically significant